Tag: antisense & RNAi therapeutics industry

  • 2024 Global Antisense & RNAi Therapeutics Market Report: Key Drivers, Size, and Leading Segments

    2024 Global Antisense & RNAi Therapeutics Market Report: Key Drivers, Size, and Leading Segments

    Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

    What Growth Rate is Predicted for the Antisense & RNAi Therapeutics Market for 2024-2033?

    The market size for antisense & rnai therapeutics has seen a speedy expansion in the recent past. The market is predicted to rise from $1.59 billion in 2023 to $1.77 billion in 2024, marking a compound annual growth rate (CAGR) of 11.4%. The noteworthy growth during the historical timeframe is due to increased funding, technological advancements, augmented healthcare spending, swift increase in the senior population, and economic upturn in developing markets.

    In the coming years, the market for antisense & rnai therapeutics is anticipated to witness a rapid surge in growth. The market is projected to increase in size to $2.81 billion by 2028, boasting a CAGR of 12.3%. Various factors can be credited to this predicted growth during the forecast period, such as enhanced access to healthcare, an increasing trend in cancer prevalence, and a boost in demand for antisense and rnai therapeutics because of the covid-19 pandemic. In the same forecast period, notable trends are expected to include concentrated efforts in the research and development of RNA therapeutics for rare diseases, the use of nanoparticle technology, the creation of new and enhanced antisense and rnai therapeutics, and collaborations with different companies for product innovation and revenue growth enhancement.

    Claim Your Free Sample of the Global Antisense & RNAi Therapeutics Market Report Today!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp

    What Drivers Are Enhancing the antisense & rnai therapeutics Market’s Growth?

    The escalating cases of coronary artery problems, neurodegenerative disorders, and infectious diseases are anticipated to boost the demand for the antisense & RNAi therapeutics market. Gene suppression strategies such as RNA interference and antisense oligonucleotides are employed for the treatment of numerous neurodegenerative diseases by rectifying mutant genes. As per the National Institute of Environmental Health Sciences, Alzheimer’s disease and Parkinson’s disease are the most prevalent neurodegenerative conditions impacting millions worldwide. In the USA, around 6.2 million people might have Alzheimer’s disease. According to January 2023 data, roughly 500,000 people in the USA have been diagnosed with Parkinson’s disease. Thus, the rising incidence of several neurodegenerative diseases and infectious diseases is predicted to propel the growth of the antisense & RNAi therapeutics market.

    What Segments Are Central to the Antisense & RNAi Therapeutics Market?

    1) By Technology: RNA Interference, Antisense RNA

    2) By Route of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods

    3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

    What Emerging Trends Are Influencing Antisense & RNAi Therapeutics Industry Dynamics?

    In the antisense & RNAi therapeutics market, leading companies are adopting strategic moves like partnerships and collaborations to hold their ground amid mounting competition. Such strategic collaborations involve two or more firms working jointly towards a shared goal or objective. For instance, in January 2023, Orbit Discovery Limited, an American firm that provides peptide discovery services, entered into a partnership with UK-based SanegeneBio Inc. which specializes in creating novel RNAi-based medicines. The partnership is aimed at identifying tissue-specific RNA therapeutics delivery for effective gene knockdown, with an end goal of developing an advanced RNAi therapeutics portfolio. The partnership includes hit identification and internalization studies conducted within cells, while Sanegene has the option to further work on the hits generated from the screening procedures, utilizing Orbit’s exclusive technology for swift peptide lead discovery. Orbit Discovery’s unique peptide display engine facilitates the screening of extensive peptide libraries, allowing for a faster discovery of pertinent peptide leads based on affinity and functional screens.

    Order Now for Fast Delivery of Your Antisense & RNAi Therapeutics Market Report!

    https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

    Which Geographic Locations Are Critical to the Growth of the Antisense & RNAi Therapeutics Market?

    North America was the largest region in the antisense & RNAi therapeutics market in 2023. The regions covered in the antisense & rnai therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    The Antisense & RNAi Therapeutics Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the antisense & rnai therapeutics market, its market share, and analyzes key competitors along with their market positions.

    The Table Of Content For The Antisense & RNAi Therapeutics Market Include

    1. Antisense & RNAi Therapeutics Market Executive Summary

    2. Antisense & RNAi Therapeutics Market Segments

    3. Antisense & RNAi Therapeutics Market Size And Template Market Growth Rate

    4. Key Antisense & RNAi Therapeutics Market Trends

    5. Major Antisense & RNAi Therapeutics Market Drivers

    ……

    25. Key Mergers And Acquisitions In The Antisense & RNAi Therapeutics Market

    26. Top Antisense & RNAi Therapeutics Companies

    27. Antisense & RNAi Therapeutics Market Opportunities And Strategies

    28. Antisense & RNAi Therapeutics Market, Conclusions And Recommendations

    29. Appendix

    Discover Related Reports by The Business Research Company:

    Anti-Hypertensive Drugs Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

    Neurodegenerative Disorder Therapeutics Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

    Biosimilar Hormones Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

    Learn More About The Business Research Company

    The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Antisense & RNAi Therapeutics Market Growth Analysis Till 2033 By The Business Research Company

    Antisense & RNAi Therapeutics Market Growth Analysis Till 2033 By The Business Research Company

    The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

    Rapid Growth Trajectory

    • The antisense & RNAi therapeutics market size has surged in recent years.
    • From $1.59 billion in 2023 to $1.77 billion in 2024, it boasts a Compound Annual Growth Rate (CAGR) of 11.4%.
    • Growth in the historic period attributed to:
      • Rise in funding.
      • Advancement in technologies.
      • Increase in healthcare expenditure.
      • Rapid growth in elderly population.
      • Economic growth in emerging markets.

    Future Projections

    • Antisense & RNAi therapeutics market projected to reach $2.81 billion in 2028.
    • CAGR expected to rise to 12.3%.
    • Forecast period growth attributed to:
      • Increased healthcare access.
      • Rising prevalence of cancer.
      • COVID-19’s impact, increasing demand for antisense and RNAi therapeutics.

    Read More On The Antisense & RNAi Therapeutics Market Report 2024 – https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

    Emerging Demand for Neurodegenerative Disorders & Infectious Diseases

    • Rise in coronary artery diseases, neurodegenerative disorders, and infectious diseases contribute to demand.
    • Gene suppression approaches utilized for treatment.
    • Alzheimer’s disease and Parkinson’s disease most prevalent neurodegenerative diseases globally.
    • Growing prevalence expected to drive market growth.

    Major Players in the Market

    • Companies contributing to the market’s growth include:
      • Biogen Inc.
      • Ionis Pharmaceuticals Inc.
      • Alnylam Pharmaceuticals Inc.
      • Arrowhead Pharmaceuticals Inc.
      • Moderna Inc.
      • Sanofi S.A.
      • And many more…

    Strategic Collaborations Driving Innovation

    • Major companies engage in partnerships to sustain competitiveness.
    • Collaborations aimed at achieving common goals.
    • Example: Orbit Discovery Limited partnered with SanegeneBio Inc. for RNA therapeutics development.
    • Collaboration between AstraZeneca PLC and Ionis Pharmaceuticals Inc. for Eplontersen development.

    Market Segmentation

    • Segmented by:
      1. Technology: RNA Interference, Antisense RNA
      2. Route of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
      3. Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

    Regional Dominance

    • North America led the antisense & RNAi therapeutics market in 2023.

    The antisense & RNAi therapeutics market presents a promising landscape for innovation and growth. With strategic collaborations, technological advancements, and rising healthcare demands, this sector is poised for continued expansion. As research and development efforts intensify, addressing critical medical needs like neurodegenerative disorders and infectious diseases, the market is set to fulfill its potential, providing novel solutions for global health challenges.

    Request for A Sample Of The Global Antisense & RNAi Therapeutics Market Report:
    https://www.thebusinessresearchcompany.com/sample_request?id=3389&type=smp